Larimar Therapeutics, Inc. (LRMR) Stock Analysis & Investment Frameworks
Larimar Therapeutics, Inc. (LRMR) stock analysis on Invetso. Review Larimar Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Larimar Therapeutics, Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Larimar Therapeutics, Inc. Key Financial Metrics
- Market Cap: $248.28M
- Revenue: $N/A
- ROE: -137.39%
- ROIC: -135.25%
- Dividend Yield: N/A
About Larimar Therapeutics, Inc.
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.